Samantha DiGrande

November 15, 2018

Experts from Venable, Alkermes, and Novartis provide updates to the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and explain the differences between inter partes review (IPR) and post grant review (PGR) litigation.

November 15, 2018

During the first day of the SMi Biosimilars Meeting held in Iselin, New Jersey, from November 14-15, 2018, Christina Yunis, global biosimilars market development lead at Pfizer, discussed the sustainability of and challenges seen in the biosimilars market from an industry perspective.

November 14, 2018

Pfizer announced today that it has launched its epoetin alfa biosimilar, Retacrit, at a substantial discount to the reference product, Epogen.

November 13, 2018

Innovent Biologics, a China-based biopharmaceutical company, announced that its new drug application for its proposed adalimumab biosimilar IBI303, referencing Humira, was accepted by the National Medical Products Administration.

November 12, 2018

When treating any disease, adherence is key. Specifically, however, in inflammatory bowel disease (IBD), adhering to biologic therapy is critical in the management of these diseases, as previous research has demonstrated that a medication possession ratio (MPR) of less than 0.86 significantly increases the risk of disease flare.

November 10, 2018

Genentech says that the biosimilar company benefited from its proprietary information, and a hearing is scheduled for December 13, 2018.

November 09, 2018

During the Community Oncology Alliance Payer Summit, held October 29-30, 2018, The Center for Biosimilars® had the opportunity to sit down with several oncologists to discuss their opinions on and experiences with biosimilars.

November 08, 2018

After the votes from the midterm elections were counted Tuesday and the Democrats had gained a majority in the US House of Representatives while Republicans reinvigorated their hold on the Senate, it was clear that a hot topic on voters’ minds was the high cost of drugs in the United States; however, questions remain as to what the newly elected officials will be able to accomplish to reduce prices.

November 07, 2018

According to the earnings report, aflibercept sales in the United States increased 7% to $1.02 billion versus third quarter 2017 results.

November 07, 2018

Elaine Herrmann Blais, partner; Scott Lassman, partner; and Alexandra Valenti, associate at Goodwin, covered 3 areas of topics ranging from the Biologics Price Competition and Innovation Act litigation, updates on the Patent Trial and Appeal Board, and recent regulatory and FDA issues related to biosimilars.